US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Inify Laboratories signs agreement with University Hospitals Plymouth NHS Trust to support faster prostate cancer diagnostics

South Oxfordshire, UK, 8th June 2026 – Inify Laboratories, a unique laboratory service that provides diagnostics within pathology, today announced that it has entered into an agreement with University Hospitals Plymouth NHS Trust (UHP) to launch a service evaluation. The evaluation aims to support the consistent delivery of a 7-day histopathology turnaround time and improve performance improvement against the 28-day Faster Diagnosis Standard (FDS). The partnership seeks to ensure patients with suspected prostate cancer receive timely, high-quality diagnostic results.   Across the

Inify Laboratories announces CQC registration and full operational launch of its state-of-the-art UK histopathology laboratory

South Oxfordshire, UK – May 27, 2026 – Inify Laboratories, a unique laboratory service that provides diagnostics within pathology, today announced that it has successfully achieved registration with the Care Quality Commission (CQC), marking a major milestone in the company’s UK expansion and confirming that the laboratory is now fully operational and open to receive clinical histopathology samples from healthcare providers across the United Kingdom.   Located in South Oxfordshire, the newly established laboratory has been purpose built to support high-quality, histopathology

Inify Laboratories AB (publ) – Bulletin from the Annual General Meeting 2026

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders’ Annual General Meeting on May 20, 2026. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main resolutions, for further details please refer to the notice available on the company's website.   Adoption of the accounts The Annual General Meeting adopted the balance sheet and income statement as well as the consolidated balance sheet and consolidated income statement for the period January 1, 2025 – December

Inify Laboratories: Progress in the dialogue with NHS in the UK and continued growth in Sweden

STOCKHOLM – April 29, 2026 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, today announces significant progress in its UK market entry and continued sales growth in Sweden during the first quarter. Sales increased compared to the same period last year, with the company’s Swedish subsidiary delivering positive results for the sixth consecutive quarter. At the same time, Inify has made important progress in the UK through advancing discussions with the NHS at both national and hospital levels.   “We are very encouraged by the

Inify Laboratories has signed an agreement with Region Jämtland Härjedalen for prostate cancer diagnostics

STOCKHOLM – April 24, 2026 - Inify Laboratories, a unique laboratory service that provides diagnostics in pathology, has entered into an agreement with the Swedish Region Jämtland Härjedalen. The agreement involves the delivery of specialised prostate cancer diagnostics with the aim of shortening waiting times for results to patients with suspected cancer.   "The collaboration means that the region's patients undergoing prostate cancer investigation are offered diagnostics in a completely digital and traceable workflow with the highest possible patient safety", says Meriana Findakly,

Inify Laboratories – notice of Annual General Meeting on May 20, 2026

Stockholm – April 15, 2026 – Inify Laboratories AB (publ), a unique laboratory service provider within pathology and diagnostics, hereby invites its shareholders to Annual General Meeting on May 20, 2026. Please find attached the invitation including agenda and details on how to register and vote. The invitation is also available on the company’s website: www.inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com.   ###     About Inify Laboratories The future of diagnostics Inify

Inify Laboratories - Annual Report 2025

Stockholm – April 15, 2026 – Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, presents its Annual Report for the fiscal year ended December 31, 2025. The annual report is attached to this press release and is also available on the company’s website: www.inify.com. Printed copies of the report will be distributed upon request sent to e-mail: ir@inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com   ###     About Inify Laboratories The

Inify Laboratories – New share capital registered

Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 4 December 2025 regarding the resolution to issue 26,266,866 new shares in a private placement (the "Private Placement Shares") and 2,304,563 new shares in a repair issue (the "Repair Issue Shares"). The share capital increase pertaining to the issuance of the Private Placement Shares and the Repair Issue Shares has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). The Company's new registered share capital is SEK 6,945,746.803089, divided on 107,474,

Gastrointestinal Service Launch and Progress in the UK Expansion

During the foruth quarter of 2025, Inify gained access to its new facilities in Milton Park, UK. In September, Inify launched its gastrointestinal service in Sweden, successfully receiving its first samples the same month. In the panel discussion for the fourth quarter of 2025, Inify’s CEO Fredrik Palm, Product Manager Kristian Eurén and the panel lead Ole Eikland discuss key highlights of the period. Sales in the fourth quarter increased by 33% compared to the same period last year and by 66% for the full year. During the quarter, Inify gained access to its new facilities in

Inify Laboratories: Solid topline growth, strong UK development, and positive response to gastrointestinal diagnostics

STOCKHOLM – February 25, 2026 - Inify Laboratories, a unique laboratory service that provides diagnostics within pathology, reports continued sales growth in the fourth quarter of 2025. Significant progress has been made in establishing its UK laboratory as well as a positive market response to its gastrointestinal diagnostics services in Sweden.   Sales growth during the quarter was driven primarily by prostate cancer diagnostics, increasing by 33% compared to the same period last year, and by 62% for the full year.   “We continue to see strong demand for our diagnostics, which

Correction: Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, 30 January 2026, Reference is made to the stock exchange announcement made by Inify Laboratories AB (publ.) (the "Company") on 27 January 2026 regarding allocation of new shares to primary insiders in the repair issue announced by the Company on 9 December 2025 (the "Repair Issue"). The number of shares allocated to board member Martin Ingvar was incorrectly stated as 67,132 in the announcement of 27 January 2026. The correct number of shares allocated to Ingvar in the Repair Issue is 67,372. Consequently, Ingvar will, subject to the completion of the Repair Issue, own

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, 27 January 2026; Inify Laboratories AB (publ.) (the "Company") announces that the below primary insiders were allocated new shares at the subscription price in the repair issue announced by the Company on 9 December 2025 (the "Repair Issue"), as further specified in the attached notification forms:   -          Monsun AS, a company closely associated with board member Magne Jordanger, has been allocated 898,204 Shares in the Repair Issue. Magne Jordanger will, through the companies Monsun AS and Gallivant S.a.r.l. and subject to completion of the Repair Issue and

Inify Laboratories – Final Results of the Repair Issue

STOCKHOLM – 27 January 2026 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 12 January 2026 regarding the commencement of the subscription period in a fully guaranteed repair issue of 2,304,563 new shares (the "Offer Shares") in the Company (the "Repair Issue"), at an offer price of NOK 3.50 per Offer Share (the "Offer Price"), with gross proceeds of approximately NOK 8 million. The subscription period in the Repair Issue expired on 26 January 2026 at 16:30 hours (CET). By the end of the subscription period, the Company had received

Inify Laboratories – Commencement of subscription period for Repair Issue

STOCKHOLM – 12 January 2026 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 19 December 2025 regarding the final results of the fully guaranteed private placement (the "Private Placement"). Further, reference is made to the stock exchange announcement made by the Company on 17 December 2025 and previous announcements regarding the fully guaranteed repair issue of 2,304,563 new shares (the "Repair Issue"). The Repair Issue will be directed pro-rata towards existing shareholders that did not participate in the Private Placement and who

Inify Laboratories - mandatory notification of trade

Stockholm – 19 December 2025 – Inify Laboratories AB (publ) (the "Company") announces that the below primary insider was allocated new shares at the subscription price in the private placement announced by the Company on 9 December 2025 (the "Private Placement"), as further specified in the attached notification forms: -          Gallivant S.à r.l. and Monsun AS, companies closely associated with board member Magne Jordanger, have been allocated 17,167,701 and 3,347,788 new shares, respectively, in the Private Placement (in aggregate: 20,515,489 new shares). Gallivant S.à r.l. and

Inify Laboratories announces final results of fully guaranteed private placement

STOCKHOLM – 19 December 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (publ) (the "Company") on 9 December 2025 regarding the fully guaranteed private placement of new shares in the Company (the “Private Placement Shares”) with gross proceeds of approximately NOK 92 million with a minimum subscription per subscriber of the NOK equivalent of EUR 100,000, directed pro-rata towards existing shareholders holding more than 1,000,000 shares in the Company (the “Private Placement”), and the fully guaranteed repair issue of approximately NOK 8 million (

Inify Laboratories: Key information regarding Repair Issue

Reference is made to the stock exchange announcement published today, 17 December 2025, regarding the preliminary results of the private placement of new shares (the "Private Placement") in Inify Laboratories AB (publ) (the "Company"), where it was announced that the Company will carry out a fully guaranteed repair issue of new shares in the Company with gross proceeds of approximately NOK 8 million (the "Repair Issue").   The Repair Issue will, subject to applicable securities law, be directed pro-rata towards all existing shareholders in the Company, other than the shareholders

Inify Laboratories announces preliminary results of fully guaranteed private placement

STOCKHOLM – 17 December 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 9 December 2025 regarding the fully guaranteed private placement of new shares in the Company (the “Private Placement Shares”) with gross proceeds of approximately NOK 92 million with a minimum subscription per subscriber of the NOK equivalent of EUR 100,000, directed pro-rata towards existing shareholders holding more than 1,000,000 shares in the Company (the “Private Placement”), and the fully guaranteed repair issue of approximately NOK 8 million (the “

Inify Laboratories - notification of trade

Stockholm, Sweden, December 16, 2025; Inify Laboratories AB (publ.) has been notified that the following transactions have been completed by a primary insider in Inify; Fredrik Palm, CEO and primary insider in Inify, has acquired 12,000 shares in Inify at an average price of NOK 3.383 per share on December 16th. After the transaction, Palm holds 103,049 shares in the company.     This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.   For further

Inify Laboratories announces application periods for fully guaranteed private placement and fully guaranteed repair issue

STOCKHOLM – 9 December 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the “Company”) on 12 November 2025, regarding a proposed fully guaranteed share issue generating gross proceeds of approximately NOK 100 million, and the extraordinary general meeting held 4 December 2025 which resolved on the proposed share issue. The general meeting resolved to launch the fully guaranteed private placement of new shares (the “Private Placement Shares”) with gross proceeds of approximately NOK 92 million with a minimum subscription per subscriber of the NOK

Bulletin from the extraordinary general meeting of Inify Laboratories AB

Today, December 4, 2025, an extraordinary general meeting was held in INIFY Laboratories AB, reg. no. 559345-4431 (the "Company"). At the meeting, 66,655,976 shares were represented, corresponding to 84.5 per cent of the total number of shares and votes in the Company. Below follows a summary of the resolution adopted at the meeting. Resolution on directed share issues The general meeting resolved, in accordance with the board of directors' proposal, on a directed issue of shares to SB1 Markets AS for onward transfer to major shareholders in the Company (the "Private Placement") and

Inify Laboratories: Board announces updated timetable for settlement in proposed Private Placement and Repair Issue

STOCKHOLM – December 3, 2025 - The board of directors of Inify Laboratories AB ("Inify" or the "Company") announces its intention to postpone the last date of payment in the Company's proposed share issues announced on November 12, 2025, (the "Private Placement" and the "Repair Issue" respectively). The final payment date is intended to be postponed to March 25, 2026, providing shareholders with additional time to procure the necessary funds to participate in the Private Placement and the Repair Issue. The postponement of the last date of payment will also affect the expected final date

Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025

Stockholm – November 12, 2025 - Inify Laboratories AB (publ), a unique laboratory service that provides cancer diagnostics within pathology, hereby invites its shareholders to Extraordinary General Meeting on December 4, 2025. Please find attached the invitation including attachment, agenda and details on how to register and vote. The invitation is also available on the company's website: www.inify.com 

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media